Lineage Capex To Revenue from 2010 to 2025

LCTX Stock  USD 0.63  0.05  7.35%   
Lineage Cell Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue will likely drop to 0.06 in 2025. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.0678
Current Value
0.0644
Quarterly Volatility
0.72522062
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 10.8 M, as well as many indicators such as Price To Sales Ratio of 22.99, Dividend Yield of 0.0015 or PTB Ratio of 2.8. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
  
Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Lineage Cell Therapeutics over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Lineage Cell's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Pretty Stable
   Capex To Revenue   
       Timeline  

Lineage Capex To Revenue Regression Statistics

Arithmetic Mean0.54
Geometric Mean0.24
Coefficient Of Variation134.11
Mean Deviation0.55
Median0.24
Standard Deviation0.73
Sample Variance0.53
Range2.2932
R-Value(0.23)
Mean Square Error0.53
R-Squared0.05
Significance0.38
Slope(0.04)
Total Sum of Squares7.89

Lineage Capex To Revenue History

2025 0.0644
2024 0.0678
2023 0.0753
2022 0.0281
2021 0.0909
2020 0.0828
2019 0.3

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.07  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.